Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck's Keytruda Keeps Nipping At Opdivo's Heels

Executive Summary

In the US there are more new starts on Keytruda than any other immunotherapy, Merck says in first-quarter earnings report.

You may also be interested in...



First-Line Chemo Combo Data Help Merck's Keytruda Power Past Opdivo

Keytruda sales are soaring on first-line lung cancer use, but with many new filings and approvals, Merck tells its second-quarter earnings call it's just the beginning.

Bristol Touts Opdivo's Stability – And Diversity – In Strong Q2

The recently launched Opdivo/Yervoy combination already has a leading position in first-line kidney cancer in the US – with a 30% share of new patients – but has been rejected in Europe.

Pharma Q2 Results Preview: AstraZeneca, Roche, Merck And BMS

Over two days, stakeholders will get a complete picture of the checkpoint inhibitor market as the four major immuno-oncology sponsors report second quarter sales and earnings. 

Related Content

Related Companies

Latest News
UsernamePublicRestriction

Register

SC123011

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel